{"public_id":"cl_a3019c80da37ecabe07f5fbf5f11d18c","status":"active","superseded_by_public_id":null,"corpus_id":205099724,"text":"Rates of serious adverse events (47% vs. 49%) and death during the study (4% vs. 6%) were similar between the ixazomib and placebo groups, though adverse events of at least grade 3 severity were more frequent with ixazomib (74% vs. 69%).","confidence":0.85,"paper":{"corpus_id":205099724,"title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","url":"https://sah.borca.ai/papers/205099724"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.85,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_3ba8fbe8a8858684fb0b66bd368e9544","name":"serious adverse events","description":"Adverse events meeting seriousness criteria, tracked as a safety outcome in the trial.","types":["safety outcome"],"url":"https://sah.borca.ai/concepts/co_3ba8fbe8a8858684fb0b66bd368e9544"},{"public_id":"co_9973c8f3ea130c99a55c1d4138e0651e","name":"ixazomib","description":"An oral proteasome inhibitor evaluated in combination with lenalidomide-dexamethasone for relapsed or refractory multiple myeloma in this trial.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_9973c8f3ea130c99a55c1d4138e0651e"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_a3019c80da37ecabe07f5fbf5f11d18c"}